459 related articles for article (PubMed ID: 37020586)
21. Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease.
Bieghs V; Trautwein C
Hepatobiliary Surg Nutr; 2014 Dec; 3(6):377-85. PubMed ID: 25568861
[TBL] [Abstract][Full Text] [Related]
22. Autophagy, NAFLD and NAFLD-Related HCC.
Wu WKK; Zhang L; Chan MTV
Adv Exp Med Biol; 2018; 1061():127-138. PubMed ID: 29956211
[TBL] [Abstract][Full Text] [Related]
23. NASH, Fibrosis and Hepatocellular Carcinoma: Lipid Synthesis and Glutamine/Acetate Signaling.
Sunami Y
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32947972
[TBL] [Abstract][Full Text] [Related]
24. The Natural Course of Non-Alcoholic Fatty Liver Disease.
Calzadilla Bertot L; Adams LA
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
[TBL] [Abstract][Full Text] [Related]
25. Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different.
Malnick SDH; Alin P; Somin M; Neuman MG
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555867
[TBL] [Abstract][Full Text] [Related]
26. Wnt/beta-catenin signaling and its modulators in nonalcoholic fatty liver diseases.
Shree Harini K; Ezhilarasan D
Hepatobiliary Pancreat Dis Int; 2023 Aug; 22(4):333-345. PubMed ID: 36448560
[TBL] [Abstract][Full Text] [Related]
27. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
[TBL] [Abstract][Full Text] [Related]
28. Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function.
Zhang J; Zhang W; Yang L; Zhao W; Liu Z; Wang E; Wang J
Phytomedicine; 2023 Jan; 109():154589. PubMed ID: 36610145
[TBL] [Abstract][Full Text] [Related]
29. Hepatic Outcomes of Nonalcoholic Fatty Liver Disease Including Cirrhosis and Hepatocellular Carcinoma.
Alqahtani SA; Chan WK; Yu ML
Clin Liver Dis; 2023 May; 27(2):211-223. PubMed ID: 37024203
[TBL] [Abstract][Full Text] [Related]
30. Emerging novel targets for nonalcoholic fatty liver disease treatment: Evidence from recent basic studies.
Wang GY; Zhang XY; Wang CJ; Guan YF
World J Gastroenterol; 2023 Jan; 29(1):75-95. PubMed ID: 36683713
[TBL] [Abstract][Full Text] [Related]
31. Emerging role of aging in the progression of NAFLD to HCC.
He Y; Su Y; Duan C; Wang S; He W; Zhang Y; An X; He M
Ageing Res Rev; 2023 Feb; 84():101833. PubMed ID: 36565959
[TBL] [Abstract][Full Text] [Related]
32. Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease.
Ramanathan R; Ali AH; Ibdah JA
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806284
[TBL] [Abstract][Full Text] [Related]
33. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Chow MD; Lee YH; Guo GL
Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
[TBL] [Abstract][Full Text] [Related]
34. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
Perumpail RB; Wong RJ; Ahmed A; Harrison SA
Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
[TBL] [Abstract][Full Text] [Related]
35. Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators.
Piccinin E; Villani G; Moschetta A
Nat Rev Gastroenterol Hepatol; 2019 Mar; 16(3):160-174. PubMed ID: 30518830
[TBL] [Abstract][Full Text] [Related]
36. The role of cGAS-STING signalling in liver diseases.
Chen R; Du J; Zhu H; Ling Q
JHEP Rep; 2021 Oct; 3(5):100324. PubMed ID: 34381984
[TBL] [Abstract][Full Text] [Related]
37. Gene Polymorphisms and Biological Effects of Vitamin D Receptor on Nonalcoholic Fatty Liver Disease Development and Progression.
Tourkochristou E; Mouzaki A; Triantos C
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175993
[TBL] [Abstract][Full Text] [Related]
38. Adaptive immunity: an emerging player in the progression of NAFLD.
Sutti S; Albano E
Nat Rev Gastroenterol Hepatol; 2020 Feb; 17(2):81-92. PubMed ID: 31605031
[TBL] [Abstract][Full Text] [Related]
39. Recent updates on targeting the molecular mediators of NAFLD.
Wang J; Wang L; Zhang XJ; Zhang P; Cai J; She ZG; Li H
J Mol Med (Berl); 2023 Feb; 101(1-2):101-124. PubMed ID: 36792729
[TBL] [Abstract][Full Text] [Related]
40. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
